{
  "docId": "019de070-c58c-706c-98f1-9eec26811648",
  "docSlug": "2a1e5b2d3a1cb25fe50abb3e75ae9bdf",
  "documentTitle": "Alkermes | Investor Day Presentation Deck | 144 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 77,
  "pageCount": 132,
  "prevPage": 76,
  "nextPage": 78,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 0,
  "notes": "RP2D = Recommended Phase 2 Dose; SC = Subcutaneous; q7d = every 7 days.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c58c-706c-98f1-9eec26811648/77",
  "deckHref": "/decks/019de070-c58c-706c-98f1-9eec26811648",
  "deckJsonHref": "/decks/019de070-c58c-706c-98f1-9eec26811648.json",
  "deckAnchorHref": "/decks/019de070-c58c-706c-98f1-9eec26811648#slide-77",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.91,
        "x": 0.056,
        "y": 0.248
      },
      "kind": "list",
      "text": "SC 3 mg q7d nemvaleukin selected as recommended phase 2 dose (RP2D) for ARTISTRY-2 efficacy expansion stage",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04899553-c01f-4ab1-aa56-d2f821571255",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.39,
        "x": 0.07,
        "y": 0.525
      },
      "kind": "list",
      "text": "Clinical benefit (stable disease) observed",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10bd923d-f099-4db1-b37b-cbd65505fd7b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.65,
        "x": 0.056,
        "y": 0.663
      },
      "kind": "list",
      "text": "Phase 2 efficacy expansion initiated based on totality of dose escalation data",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "36fdab51-abc5-46fd-aea3-c47160ca2122",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.89,
        "x": 0.07,
        "y": 0.375
      },
      "kind": "list",
      "text": "Acceptable safety and tolerability profile consistent with the anticipated pharmacological effect and that observed with intravenous nemvaleukin",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "732b6aff-9144-4254-b5e1-392d3269f2c5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.89,
        "x": 0.07,
        "y": 0.468
      },
      "kind": "list",
      "text": "Dose-dependent increases in NK cell and CD8+ T cell activation and minimal increase in immunosuppressive Tregs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81f72ce0-e6bc-4282-9819-fd5d5039b032",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.056,
        "y": 0.595
      },
      "kind": "list",
      "text": "Additional ARTISTRY-2 data to be presented at future medical meeting",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b3773cb-859e-49af-a2d8-5c289984b654",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.89,
        "x": 0.056,
        "y": 0.312
      },
      "kind": "list",
      "text": "Selection of RP2D based on totality of data including PK/PD, safety and efficacy during dose escalation phase",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cbd9a6d2-fe6f-4728-8a38-fbbecfbc5861",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.39,
        "x": 0.056,
        "y": 0.888
      },
      "kind": "source-note",
      "text": "Treg = regulatory T cell, NK = Natural Killer, PK/PD = Pharmacokinetic/Pharmacodynamic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7920d94a-fa50-4b4c-a5a9-182353a4aabd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.056,
        "w": 0.488,
        "x": 0.056,
        "y": 0.125
      },
      "kind": "title",
      "text": "ARTISTRY-2: RP2D Determined",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "75e95483-50b3-480a-b5b1-8147fd12f5e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}